CMV-Specific T-Cells for CMV Infections in Immunocompromised Patients

Phase 1, open-label, single-arm trial of adimlecleucel in cytomegalovirus infection (CMV), sponsored by University of Wisconsin–Madison. Primary endpoints: Number of Participants Who Drop-Out Before T-Cell Transfer up to 21 days, Number of Days from Participant Enrollment to Administration of CMV-VST up to 21 days and 7 more. Started Feb 2020; status: terminated.